Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines that are designed to precisely target disease pathology, and Terray Therapeutics, Inc., a biotechnology company focused on improving human health by transforming the speed, cost, and success rate of small molecule drug development using computation integrated with novel data at scale, announced today that they have entered into a strategic collaboration to jointly discover and develop small molecule medicines against transcription factor targets of interest. The collaboration combines Odyssey’s expertise in immunology and transcription factor biology with Terray’s complementary expertise in immunology and integrated AI platform, tNova, which leverages proprietary experimental data at scale to power its AI capabilities. Together, the companies will work to develop first-in-class therapeutic candidates for high-interest targets with potential application across inflammatory diseases.
“We are excited to collaborate with Terray, whose integrated computational and experimental platform offers a powerful complement to our team’s expertise in immunology, and experience in reconstituting functional transcription factors and drug discovery,” said Gary D. Glick, Ph.D., founder and CEO of Odyssey Therapeutics. “This collaboration has the potential to create first-in-class therapeutics capable of driving meaningful benefit for patients in inflammatory diseases with high unmet need.”
Also Read: AbbVie and Gedeon Richter Collaborate on Neuropsychiatric Target Discovery
Under the terms of the collaboration agreement, the parties will collaborate to identify one or more development candidates directed at targets of interest. Odyssey will provide enabling background IP and structural and protein biology know-how for use in Terray’s tNova drug discovery platform for initial hit-finding and lead maturation activities. Thereafter, the parties will share responsibilities for the research, development and commercialization of the program pursuant to written plans under the agreement and share collaboration losses and collaboration profits equally.
Jacob Berlin, Ph.D., Chief Executive Officer, Terray Therapeutics, said: “We are thrilled to collaborate with Odyssey. At Terray, our proprietary ultra-miniaturized chemistry platform enables unique generative AI capabilities for the discovery and development of small molecule therapeutics. This approach is a perfect complement for Odyssey’s transcription factor biology expertise. We believe that our discovery capabilities and combined expertise in immunology affords us the opportunity to solve incredibly hard challenges and bring relief to patients.”
SOURCE: Odyssey Therapeutics